These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 25584786)

  • 1. Prion degradation pathways: Potential for therapeutic intervention.
    Goold R; McKinnon C; Tabrizi SJ
    Mol Cell Neurosci; 2015 May; 66(Pt A):12-20. PubMed ID: 25584786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective processing and metabolism of disease-causing mutant prion proteins.
    Ashok A; Hegde RS
    PLoS Pathog; 2009 Jun; 5(6):e1000479. PubMed ID: 19543376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNAi: a novel strategy for the treatment of prion diseases.
    Kong Q
    J Clin Invest; 2006 Dec; 116(12):3101-3. PubMed ID: 17143323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysosomal Quality Control in Prion Diseases.
    Majumder P; Chakrabarti O
    Mol Neurobiol; 2018 Mar; 55(3):2631-2644. PubMed ID: 28421536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental approaches to TSE prevention via inhibition of prion formation.
    Politopoulou G
    Protein Pept Lett; 2004 Jun; 11(3):249-55. PubMed ID: 15182226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene and cell therapy for prion diseases.
    Relaño-Ginés A; Gabelle A; Lehmann S; Milhavet O; Crozet C
    Infect Disord Drug Targets; 2009 Feb; 9(1):58-68. PubMed ID: 19200016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagy induction by trehalose counteracts cellular prion infection.
    Aguib Y; Heiseke A; Gilch S; Riemer C; Baier M; Schätzl HM; Ertmer A
    Autophagy; 2009 Apr; 5(3):361-9. PubMed ID: 19182537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prion disease is accelerated in mice lacking stress-induced heat shock protein 70 (HSP70).
    Mays CE; Armijo E; Morales R; Kramm C; Flores A; Tiwari A; Bian J; Telling GC; Pandita TK; Hunt CR; Soto C
    J Biol Chem; 2019 Sep; 294(37):13619-13628. PubMed ID: 31320473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.
    Coleman BM; Harrison CF; Guo B; Masters CL; Barnham KJ; Lawson VA; Hill AF
    J Virol; 2014 Mar; 88(5):2690-703. PubMed ID: 24352465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells.
    Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
    PLoS One; 2014; 9(9):e106516. PubMed ID: 25181483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cells and prions: a license to replicate.
    Nuvolone M; Aguzzi A; Heikenwalder M
    FEBS Lett; 2009 Aug; 583(16):2674-84. PubMed ID: 19527722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the histo-molecular pathology of human prion disease.
    Baiardi S; Rossi M; Capellari S; Parchi P
    Brain Pathol; 2019 Mar; 29(2):278-300. PubMed ID: 30588685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infectivity-associated PrP(Sc) and disease duration-associated PrP(Sc) of mouse BSE prions.
    Miyazawa K; Okada H; Masujin K; Iwamaru Y; Yokoyama T
    Prion; 2015; 9(5):394-403. PubMed ID: 26555211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of neurotoxicity of pathological prion protein.
    Castilla J; Hetz C; Soto C
    Curr Mol Med; 2004 Jun; 4(4):397-403. PubMed ID: 15354870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prion Concept and Synthetic Prions.
    Legname G; Moda F
    Prog Mol Biol Transl Sci; 2017; 150():147-156. PubMed ID: 28838659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomics applications in prion biology and structure.
    Moore RA; Faris R; Priola SA
    Expert Rev Proteomics; 2015 Apr; 12(2):171-84. PubMed ID: 25795148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pathogenic mechanisms of prion diseases.
    Unterberger U; Voigtländer T
    CNS Neurol Disord Drug Targets; 2007 Dec; 6(6):424-55. PubMed ID: 18220781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol and its reciprocal association with prion infection.
    Cashion J; Zhang W; Ali T; Gilch S
    Cell Tissue Res; 2023 Apr; 392(1):235-246. PubMed ID: 35821439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
    Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
    Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of p62/SQSTM1 in prion diseases and its association with pathogenic prion protein.
    Homma T; Ishibashi D; Nakagaki T; Satoh K; Sano K; Atarashi R; Nishida N
    Sci Rep; 2014 Mar; 4():4504. PubMed ID: 24675871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.